• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • COVID-19
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

BioIntelliSense and Medically Home Partner to Enhance High Acuity Hospital Care at Home

by HITC Staff 11/10/2022 Leave a Comment

BioIntelliSense and Medically Home Partner to Enhance High Acuity Hospital Care at Home

What You Should Know:

– BioIntelliSense, Inc., a continuous health monitoring and clinical intelligence company, today announced it has entered into a strategic partnership with Medically Home Group, Inc., a technology-enabled services company that is at the forefront of the movement to decentralize care for serious or complex illnesses.

– The collaboration further expands the availability of continuous biometric data and insights to physicians and nurses caring for patients in the Medically Home model with serious, complex or high-risk illness being cared for in their homes while accelerating the adoption of medical grade BioButton® wearable devices.

BioButton Background

The rechargeable multi-parameter BioButton® wearable devices passively capture clinically validated vital signs of heart rate at rest, respiratory rate at rest and skin temperature, along with a broad range of physiologic biometrics, including activity levels, sleep tracking, body position and gait analysis. The BioCloud™ data analytics and algorithmic-based alerting enable actionable clinical triage and proactive clinical intervention through potential earlier detection of adverse trends.

The Medically Home model directly addresses the growing need for increased health system capacity and resiliency, while meeting the needs and preferences of patients, who often desire to be cared for in the comfort and convenience of their home. With the comprehensive Medically Home and BioIntelliSense solution, patients with conditions across a broad spectrum of severity, complexity, and risk can continue to be cared for safely at home with clinical accuracy, reducing the necessity for traditional building-centric care.

“BioIntelliSense provides a scalable medical-grade solution that allows for passive vital sign data collection from the home, dramatically reducing the cost and complexity of deploying traditional remote patient monitoring programs with improved patient experience,” said Pippa Shulman, DO, MPH, Chief Medical Officer, Medically Home. “As hospital capacity pressure mounts, this strategic collaboration further accelerates Medically Home’s platform reach and growing ecosystem of health systems and payers nationwide.”

Tagged With: BioIntelliSense, Biometric Data, Clinical Intelligence, data analytics, Health Systems, Heart, model, Patient Experience, Patient Monitoring, Payers, physicians, remote patient monitoring, risk, Vital

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Most Popular

Survey: Clinician Burnout Is A Public Health Crisis Demanding Urgent Action

17 Execs Share How Health IT Can Address Clinician Burnout, Staffing, & Capacity

Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care

Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care

Northwell Health Extends Contract with Allscripts Sunrise Platform Through 2027

Northwell to Deploy Epic Enterprise EHR Platform Across System

Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients

Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients

Pfizer Acquires Seagen for $43B to Tackle Cancer

Pfizer Acquires Seagen for $43B to Tackle Cancer

5 Key Trends Driving Purchasing Decisions in Healthcare IT

5 Key Trends Driving Purchasing Decisions in Healthcare IT

Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B

Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B

Dr. Arti Masturzo

Q/A: Dr. Masturzo Talks Addressing Food Insecurity with Patients

Transcarent Acquires 98point6 AI-Powered Virtual Care Platform and Care Business

Transcarent Acquires 98point6 AI-Powered Virtual Care Platform and Care Business

Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month

Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • 2023 Editorial Calendar
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2023. HIT Consultant Media. All Rights Reserved. Privacy Policy |